Literature DB >> 25370351

Determinants of recurrence after intended curative resection for colorectal cancer.

Michael Wilhelmsen1, Thomas Kring, Lars N Jorgensen, Mogens Rørbæk Madsen, Per Jess, Orhan Bulut, Knud Thygesen Nielsen, Claus Lindbjerg Andersen, Hans Jørgen Nielsen.   

Abstract

Despite intended curative resection, colorectal cancer will recur in ∼45% of the patients. Results of meta-analyses conclude that frequent follow-up does not lead to early detection of recurrence, but improves overall survival. The present literature shows that several factors play important roles in development of recurrence. It is well established that emergency surgery is a major determinant of recurrence. Moreover, anastomotic leakages, postoperative bacterial infections, and blood transfusions increase the recurrence rates although the exact mechanisms still remain obscure. From pathology studies it has been shown that tumors behave differently depending on their location and recur more often when micrometastases are present in lymph nodes and around vessels and nerves. K-ras mutations, microsatellite instability, and mismatch repair genes have also been shown to be important in relation with recurrences, and tumors appear to have different mutations depending on their location. Patients with stage II or III disease are often treated with adjuvant chemotherapy despite the fact that the treatments are far from efficient among all patients, who are at risk of recurrence. Studies are now being presented identifying subgroups, in which the therapy is inefficient. Unfortunately, only few of these facts are implemented in the present follow-up programs. Therefore, further research is urgently needed to verify which of the well-known parameters as well as new parameters that must be added to the current follow-up programs to identify patients at risk of recurrence.

Entities:  

Keywords:  colorectal cancer; disease-free survival; follow-up program; recurrence; surgery

Mesh:

Substances:

Year:  2014        PMID: 25370351     DOI: 10.3109/00365521.2014.926981

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  10 in total

1.  Clinical impact of PET/MR in treated colorectal cancer patients.

Authors:  Barbara J Amorim; Theodore S Hong; Lawrence S Blaszkowsky; Cristina R Ferrone; David L Berger; Liliana G Bordeianou; Rocco Ricciardi; Jeffrey W Clark; David P Ryan; Jennifer Y Wo; Motaz Qadan; Mark Vangel; Lale Umutlu; David Groshar; Lina G Cañamaques; Debra A Gervais; Umar Mahmood; Bruce R Rosen; Onofrio A Catalano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-29       Impact factor: 9.236

Review 2.  Surveillance after curative treatment for colorectal cancer.

Authors:  Eric P van der Stok; Manon C W Spaander; Dirk J Grünhagen; Cornelis Verhoef; Ernst J Kuipers
Journal:  Nat Rev Clin Oncol       Date:  2016-12-20       Impact factor: 66.675

3.  Tissue micro-RNAs associated with colorectal cancer prognosis: a systematic review.

Authors:  Igor Lopes Dos Santos; Karlla Greick Batista Dias Penna; Megmar Aparecida Dos Santos Carneiro; Larisse Silva Dalla Libera; Jéssica Enocencio Porto Ramos; Vera Aparecida Saddi
Journal:  Mol Biol Rep       Date:  2021-02-17       Impact factor: 2.316

Review 4.  [Hybrid imaging of the abdomen and pelvis. German version].

Authors:  Krista Elise Suarez-Weiss; Alexander Herold; Debra Gervais; Edwin Palmer; Bárbara Amorim; Joseph D King; Li Weier; Tajmir Shahein; Hanna Bernstine; Liran Domachevsk; Lina Garcia Cañamaque; Lale Umutlu; Ken Herrmann; David Groshar; Onofrio A Catalano
Journal:  Radiologe       Date:  2020-05       Impact factor: 0.635

5.  IBSP, a potential recurrence biomarker, promotes the progression of colorectal cancer via Fyn/β-catenin signaling pathway.

Authors:  Yan Chen; Ying Qin; Mengmeng Dai; Liping Liu; Yong Ni; Qinsheng Sun; Lulu Li; Yaoyao Zhou; Cheng Qiu; Yuyang Jiang
Journal:  Cancer Med       Date:  2021-05-13       Impact factor: 4.452

6.  Exploring the medication duration based on the effect of traditional Chinese medicine on postoperative stage I-III colorectal patients: a retrospective cohort study.

Authors:  Qi Shi; Shanshan Liu; Wen Li; Shaoqi Zong; Susu Han; Wei Yang; Hongjia Li; Fenggang Hou
Journal:  Oncotarget       Date:  2017-02-21

Review 7.  Epidemiology and biology of physical activity and cancer recurrence.

Authors:  Christine M Friedenreich; Eileen Shaw; Heather K Neilson; Darren R Brenner
Journal:  J Mol Med (Berl)       Date:  2017-06-15       Impact factor: 4.599

8.  Right- and left-sided colorectal cancers respond differently to traditional Chinese medicine.

Authors:  Shan-Shan Liu; Qi Shi; Hong-Jia Li; Wei Yang; Su-Su Han; Shao-Qi Zong; Wen Li; Feng-Gang Hou
Journal:  World J Gastroenterol       Date:  2017-11-14       Impact factor: 5.742

Review 9.  MicroRNAs: Clinical Relevance in Colorectal Cancer.

Authors:  Joe Thomas; Masahisa Ohtsuka; Martin Pichler; Hui Ling
Journal:  Int J Mol Sci       Date:  2015-11-25       Impact factor: 5.923

10.  Blocking the Increase of Intracellular Deuterium Concentration Prevents the Expression of Cancer-Related Genes, Tumor Development, and Tumor Recurrence in Cancer Patients.

Authors:  Beáta Zs Kovács; László G Puskás; Lajos I Nagy; András Papp; Zoltán Gyöngyi; István Fórizs; György Czuppon; Ildikó Somlyai; Gábor Somlyai
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 3.302

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.